Andrew Staron, MD

Assistant Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Andrew Staron, MD is an Assistant Professor of Medicine in Hematology & Medical Oncology at the Chobanian and Avedisian School of Medicine. He was appointed to this position after completing his residency (2015–2018) and fellowship (2019–2022) at Boston Medical Center. In his third year of fellowship, Dr. Staron was selected for the role of chief fellow. Additionally, he completed a year-long clinical and research fellowship in amyloidosis (2018–2019) at the Boston University Amyloidosis Center, under the mentorship of the director, Dr. Sanchorawala.

As a practicing hematologist at Boston Medical Center, Dr. Staron has a deep commitment to serving patients and families who are affected by various hematologic diseases and who come from diverse backgrounds, drawing upon his own upbringing in an immigrant family. His main research interest is in AL amyloidosis—a rare plasma cell disorder that leads to the accumulation of abnormal immunoglobulin light chain proteins in organs. He has been the lead author on several publications in peer-reviewed journals and given presentations related to AL amyloidosis at national and international meetings. Dr. Staron helps to oversee the clinical database at the Boston University Amyloidosis Center and is directly involved in research projects utilizing this resource. He has conducted natural history studies that described important trends in disease outcomes and explored the role of minimal residual disease assessment in AL amyloidosis. Dr. Staron is also a member of the International Society of Amyloidosis and a peer-reviewer for several journals.

Publications

  • Published 3/25/2025

    Edwards CV, Ferri GM, Villegas-Galaviz J, Ghosh S, Singh Bawa P, Wang F, Klimtchuk E, Ajayi TB, Morgan GJ, Prokaeva T, Staron A, Ruberg FL, Sanchorawala V, Giadone RM, Murphy GJ. Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition. Amyloid. 2025 Jun; 32(2):179-192. PMID: 40134188.

    Read at: PubMed

  • Published 1/31/2025

    Staron A, Sanchorawala V. Current landscape of clinical management for systemic light chain amyloidosis. Future Cardiol. 2025 Mar; 21(4):203-205. PMID: 39885778.

    Read at: PubMed

  • Published 12/10/2024

    Abdallah M, Arters F, Patel J, Edwards C, Lerner A, Petrocca F, Dockerty M, Fuller B, Godfrey A, Staron A, Sanchorawala V, Sloan JM, Bertrand K, Szalat R. Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis. Blood Adv. 2024 Dec 10; 8(23):5935-5938. PMID: 39348709.

    Read at: PubMed

  • Published 11/26/2024

    Sanchorawala V, Barroso B, Shelton A, Goetz E, Mendelson L, Joshi T, Burke N, Sloan JM, Staron A. Defying the odds: 30 years in AL amyloidosis research-recent barriers to clinical trial enrollment. Blood Adv. 2024 Nov 26; 8(22):5826-5828. PMID: 39293090.

    Read at: PubMed

  • Published 9/14/2024

    Staron A, Mendelson LM, Joshi T, Burke N, Sanchorawala V. Factors impeding organ recovery despite a deep haematological response in patients with systemic AL amyloidosis. Br J Haematol. 2024 Dec; 205(6):2268-2272. PMID: 39275899.

    Read at: PubMed

Education

  • New York Medical College, MD
  • Cornell University, BS